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Abstract 
A number of new tetracyclic psoralen derivatives were studied. The fourth ring is constituted by 
cyclopentane (4, 7 and 9), cyclohexane (11, 15 and 18) or benzene (12, 16 and 20) fused to either 
4',5' or 3,4 photoreactive double bond of tricyclic furocoumarin moiety. The 
photoantiproliferative activity of all compounds, tested on two human tumor cell lines (HeLa and 
HL-60), appeared from 8 to 22 times higher than that of the well-known photochemotherapeutic 
drug 8-methoxypsoralen (8-MOP) in HeLa, slightly higher in HL-60. Interestingly, the 
evaluation of skin phototoxicity on guinea pigs evidenced a decrease in erythema induction for 
all compounds with respect to the drug. As regards the molecular mechanism of action, the 
ability to photoadd to DNA is demonstrated by isolation and characterization of the photoadducts 
and by the ability to give rise to interstrand cross-links for the difunctional derivatives. 
 






Inside the wide field of photochemotherapy the psoralens play a significant role. In particular, 
skin diseases characterized by hyperproliferation, such as psoriasis, are effectively treated by 
means of PUVA therapy (psoralen plus UVA light).1-3 Moreover, psoralens are successfully 
employed for the treatment of cutaneous T-cell lymphoma, a T-cell mediated disorder, by an 
extracorporeal photochemotherapy called photopheresis.4,5 Nevertheless, the existence of some 
undesired side-effects limits the therapeutic use of psoralens. Indeed, both short-term (erythema, 
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hyperpigmentation) and long-term (benign keratoses, premalignant keratoses, skin cancers) 
undesired effects can occur.2 
Between psoralens, 8-methoxypsoralen (8-MOP) constitutes the drug most widely employed, 
but also 5-methoxypsoralen and 4,5',8-trimethylpsoralen hold a noticeable role in 
photochemotherapy, even though to a lesser extent.6,7 
The psoralen tricyclic moiety, due to its planarity, is able to intercalate inside base pairs of 
DNA. Upon UVA irradiation (365 nm) a photoaddition reaction between the 4’,5’ furan side 
and/or the 3,4 pyrone side double bonds and the 5,6 double bond of a pyrimidine base, generally 
thymine, can take place. The ability of the furan side monoadduct to absorb at 365 nm can allow 
the formation of diadducts involving two bases belonging to the opposite DNA strands.8 
Many psoralen derivatives have been synthesized up to now with the aim of weakening the 
undesired side effects. Inside the different lines of research, the condensation of a fourth 
benzenic or cyclohexenyl ring to the tricyclic psoralen chromophore led to some tetracyclic 
moieties endowed with interesting photobiological properties.9-15 In particular, it was shown that 
the presence of a fourth aromatic ring caused the disappearance of the skin photosensitizing 
potency, evaluated as erythema induction. Furthermore, for some benzopsoralen derivatives a 
noteworthy increase in photoantiproliferative activity on human tumor cell lines, with respect to 
8-MOP, was demonstrated. As regards the tetrahydrobenzopsoralen moiety, the most interesting 
derivatives showed a cytotoxic activity higher with respect to that exerted by the reference drug 
along with a significant decrease of skin phototoxicity.14,15 The condensation of a cyclopentane 
ring to the tricyclic psoralen nucleus was also reported.16 In detail, the synthesized 
cyclopentenepsoralen bearing the cyclopentane ring fused to the 4',5' double bond appears to 
show a slight improvement in photobiological properties, i.e. increased photoantiproliferative 
activity on human tumor cell line and diminished skin photosensitization, with respect to the 
drug 8-MOP.16 
Moreover, in previous studies it was demonstrated that the introduction of methyl groups in 
the psoralen cromophore appeared to increase significantly its ability to photobind to DNA and, 
in some cases, to improve the photobiological properties.17-19 
In this paper we studied the photobiological behaviour of a series of structurally related psoralen 
derivatives endowed with a tetracyclic nucleus and carrying two methyl groups in different 
positions. 
In detail, the derivatives taken into consideration are characterized by the presence of a 
cyclopentane (4, 7 and 9), a cyclohexane (11, 15 and 18) or a benzene (12, 16 and 20) ring fused 
to the tricyclic psoralen cromophore. The fourth ring is condensed at the level of the furan or 
pyrone photoreactive double bond. Furthermore, a methyl group is linked in the 8 position along 
with a further methyl at the level of the 4', 5' or 4 position of the tricyclic psoralen structure. 
The photoantiproliferative activity on human tumor cell lines, the skin phototoxicity on guinea 
pigs and the photoaddition to DNA were evaluated in comparison with the well-known drug 8-
MOP. Furthermore, the isolation and characterization of furan photoadducts with thymine were 
reported. 
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Results and Discussion 
 
Chemistry 
The studied compounds (4, 7, 9, 11, 12, 15, 16, 18, 20) were obtained starting from 2-
methylresorcinol (1), as shown in Scheme 1.  
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Scheme 1. Reagents: (a) ethylacetoacetate, H2SO4; (b) 2-chlorocyclopentanone; (c) NaOH; (d) 
K2CO3 , 2,3-dibromopropene; (e) N,N-diethylaniline; (f) 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone, toluene. The yields are reported in parentheses. 
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The preparation of 7, 11, 12, 15, 16 and 18, in accordance with a general approach to the 
psoralen skeleton, has been described elsewhere.9,20,21,22 
Pechmann condensation of compound 1 and ethyl acetoacetate afforded the corresponding 
hydroxycoumarin 2, which through a Williamson reaction with 2-chlorocyclopentanone gave the 
oxoether 3 in 90% yield. Cyclization of 3 in strongly alkaline solution afforded the 
ciclopentenefurocoumarin 4 in 30% yield. 
The pyrone side derivative 9 was obtained by the treatment of the hydroxycoumarin 5 with 
2,3-dibromopropene, and following cyclization of the achieved product 8 in 40% overall yield. 
Compound 20 was synthesised from hydroxycoumarin 13 in a 4-step reaction: the reaction of the 
latter with 2,3-dibromopropene, in the same manner as 8 from 5, gave the resulting ether 17 
which then was oxidized with DDQ in toluene to give 19 in 62% overall yield. Finally, the 
cyclization of 19 with N,N-diethylaniline produced the benzoderivative 20 in 52% yield. 
Compound 18 was also prepared through a different synthetic route with respect to that 
already described22 starting from 17 by reaction with the N,N-diethylaniline as base, in 57% 
yield. 
Photobiological activity 
The antiproliferative activity of the new methyl derivatives, cyclopentene- (4, 7 and 9) 
tetrahydrobenzo- (11, 15 and 18) and benzo-psoralens (12, 16 and 20) was evaluated on HeLa 
and HL-60 human tumor cell lines. The photochemotherapeutic drug 8-MOP was taken into 
account as reference compound. The results obtained after exposure to UVA light (0.793 J cm-2 
at 365 nm) are reported in Table 1 and expressed as IC50 values, i.e. the concentration of 
compound (µM) able to induce 50% cell death with respect to the control culture. 
Table 1. Cell growth inhibition and skin phototoxicity in guinea pigs in the presence of 
examined compounds and 8-MOP as reference drug 
IC50 (µM) of cell lines Skin phototoxicity 




4 0.65±0.15 2.4±0.4 0.08 + + - 
7  1.05±0.26 3.3±0.6 0.08 + + - 
9 0.66±0.16 2.8±0.6 0.08 + + - 
11 0.59±0.13 1.7±0.2 0.08 + - - 
15 0.45±0.05 2.7±0.3 0.08 - - - 
18 0.65±0.07 4.3±0.4 0.08 + - - 
12 0.63±0.06 1.8±0.2 0.19 - - - 
16 0.47±0.07 2.0±0.2 0.19 - - - 
20 0.65±0.07 1.4±0.1 0.19 - - - 
8-MOPb 10±3 5.4±0.7 0.05 + + + 
a + + +, strong with edema; + + -, strong without edema; + - -, mild; - - - absent. b taken from 
from ref. 14. 
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All the methyl derivatives are able to exert a noticeable antiproliferative activity towards 
both tumor cell lines. In detail, in the HeLa cells the IC50 values of the new compounds appear to 
be from 8 to 22 times lower with respect to that calculated for 8-MOP. As regards the human 
promyelocytic leukemia cell line, HL-60, it appears to be less sensitive toward the treatment with 
the new compounds. Indeed, the IC50 values are only slightly lower in comparison with that of 
the reference drug. It is interesting to note that, notwithstanding the remarkable antiproliferative 
activity exerted upon treatment with UVA light, none of the considered compounds show 
cytotoxic effect in the dark (data not shown). 
Comparing the above results with the chemical molecular structure of the tetracyclic methyl 
derivatives, it is evident that the extension of the tricyclic psoralen moiety, due to the 
condensation of a fourth ring, appears to be always relevant to increase the photoantiproliferative 
activity. Nevertheless, the ability to inhibit cell growth seems not to be correlated with the 
chemical structure of the fourth ring. In particular, both the steric hindrance caused by lack of 
aromaticity in the hydrogenated rings (cyclohexane for 11, 15 and 18, cyclopentane for 4, 7 and 
9) and the delocalization of the electron density due to a tetracyclic aromatic system (12, 16 and 
20) similarly affect the antiproliferative ability of the psoralen chromophore. An analogous 
consideration has to be made with regards to the role played by the methyl substituents. Indeed, 
it seems that their position (4, 4’ or 5’ of the psoralen moiety) do not constitute a critical factor 
for the cytotoxicity. In detail, it could be stated that the presence of a methyl substituent both at 
the pyrone side double bond and at the furan side double bond does not compromise the capacity 
of these site to exert their photoreactivity. 
The induction of skin phototoxicity, determined by evaluating the appearance of erythema, a 
marker of cutaneous sensitization, was investigated and the results obtained are shown in Table 
1. It can be noted that, unlike in the case of the antiproliferative activity, the chemical structure 
of the fourth condensed ring is crucial in determining the appearance of this undesired side 
effect. In particular, the benzopsoralen derivatives 12, 16 and 20 appear to be devoid of 
photosensitizing effect, even if they are applied on skin at a concentration 3.8 times higher with 
respect to that of the reference drug. As regards the derivatives characterized by the condensation 
of a cyclohexenyl ring it is noteworthy that the presence of the fourth ring at the pyrone side of 
the tricyclic psoralen moiety, along with the presence of a methyl substituent at 4’ position of the 
furan side (compound 15), constitutes the most interesting tetrahydrobenzopsoralen structure, 
since it does not induce skin phototoxicity. By contrast, with analogues 11 and 18 the appearance 
of a certain skin photosensitization was scored, even though it is significantly lower if compared 
with the effect induced by 8-MOP. Finally, the compounds 4, 7 and 9, characterized by the 
condensation of a cyclopentene ring at pyrone or furan side, induce skin phototoxicity. 
Nevertheless, it has to be underlined that also in this case the undesired side effect is diminished 




Issue in Honor of Prof. Vincenzo Tortorella ARKIVOC 2004 (v) 131-146 
ISSN 1424-6376 Page 136 ©ARKAT USA, Inc 
Photobinding to DNA 
 
It is well known that in the ground state the psoralen tryciclic moiety forms a preliminary 
complex with DNA in which the planar chromophore undergoes intercalation inside two base 
pairs.23 After UVA irradiation, the intercalated ligand photobinds covalently to DNA giving rise 
to monoadducts and diadducts. 
Similar behavior was also already observed for various tetracyclic psoralen derivatives 
carrying both a benzene10,11,14,15 or a cyclohexane11,14,15 as fourth ring. In detail, in these previous 
studies the ability of benzopsoralen and tetrahydrobenzopsoralen derivatives to photobind to 
DNA bases was widely demonstrated by the evaluation of the amount of radiolabelled 
compounds photoadded to the macromolecule10,11,14 and by the isolation and characterization of 
the monoadducts.15 In particular, it was clearly shown that the condensation of a cyclohexenyl or 
benzenic ring to a photoreactive double bond affects its photoaddition ability towards the DNA 
bases in a very different way. In detail, the steric hindrance caused by lack of aromaticity in the 
hydrogenated ring does not prevent the ability to photoaddition, while the delocalization of the 
electron density of the photoreactive double bond of the furocoumarin moiety in a tetracyclic 
aromatic system impedes its involvement in the cycloaddition.11,14,15 
In this connection, the investigation was also undertaken into the photoaddition process of 
the methyl tetrahydrobenzo and benzopsoralen derivatives. In detail, the irradiation (365 nm) of 
an aqueous solution of DNA in the presence of the considered compounds, followed by 
precipitation and acid hydrolysis, as described in the Experimental Section, allowed us to isolate 
a photoproduct characterized by a strong violet fluorescence upon exposure to 365 nm UV light. 
This characteristic is typical of furocoumarins having a 3,4-ethylenic bond within the pyrone ring 
and thus is usually retained consistent with the molecular structure of the furan side 
monoadduct.24 Furthermore, the UV absorption spectra of an ethanol solution of the isolated 
fluorescent products showed the disappearance of the peculiar furocoumarin band around 300 
nm and an evident absorption at 330 nm which gradually disappears as the irradiation time is 
increased to 254 nm (spectra not shown). This behavior further confirms the above assumption; 
indeed it was already established that the C4-cycloadducts undergo breakage upon 254 nm 
irradiation, yielding the parent compounds, i.e. the psoralen and the DNA base. 
As already demonstrated for psoralens and also for benzo and tetrahydrobenzopsoralen 
derivatives,14,15 inside DNA bases, thymine constitutes by far the preferred target of the 
photoreaction. The mass spectra of the photoproduct of the tetrahydrobenzopsoralen 11, where 
the major peak appears at m/z=395, and of the benzopsoralen 16 which shows the major peak at 
m/z=391, are consistent with a thymine-11 and a thymine-16 photoadduct, respectively (spectra 
not shown). 
As regards the cyclopentene-psoralen tetracyclic moiety, a previous study reports some 
indications on its ability to photobind covalently to DNA.16 In this connection, it appeared of 
interest to investigate the ability of 4, 7 and 9 to photoadd to the macromolecule. In detail, the 
capacity of the methyl cyclopentenepsoralen derivatives to give rise to a covalent photoadduct 
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with DNA bases was demonstrated by the isolation and characterization of the furan side 
monoadduct obtained after UVA irradiation of an aqueous solution of DNA and the above 
compounds as described in the Experimental Section. After TLC separation a fluorescent band 
appears. The UV spectrum of an ethanol solution of this photoproduct shows the typical 
characteristics of the C4-cycloadducts between the furan double bond of the furocoumarin and 
the 5,6 double bond of a pyrimidine base, i.e. an evident absorption at 330 nm and the 
disappearance of the peculiar furocoumarin band around 300 nm, present in the spectrum of 4, 7 
and 9. Photoreversion experiments provide further evidence on the photoadduct formation. In 
Figure 1, the UV absorption spectra of the photoproduct, obtained by the photoreaction between 
4 and DNA, before (line a) and after increasing periods of irradiation at 254 nm (lines b-f), is 
shown as an example. 
Figure 1. UV absorption spectra of an ethanol solution of furan cycloadduct obtained from DNA 
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The analysis of the fluorescent photoproducts by mass spectrometry confirms also for 
cyclopentenepsoralen derivatives 4, 7 and 9 the preference to covalent photoadd to pyrimidine 
bases, and in particular to thymine. Indeed, the mass spectra show the presence of a major peak 
at m/z=381 which is consistent with a thymine-cyclopentenepsoralen cycloadduct (spectra not 
shown). 
In particular, the results obtained allow us to affirm that, similarly to what was demonstrated 
for the tetrahydrobenzosporalen moiety, the cyclopentane ring fused at a photoreactive double 
bond did not seem to compromise its DNA photoaddition capacity. 
 
Cross-linking 
The furan side monoadduct possesses the important property to absorb at 365 nm. This ability 
allows the formation of interstrand cross-links. As already stated, the condensation of the 
aromatic fourth ring renders the tetracyclic benzopsoralens monofunctional molecules, indeed 
both 16 and 20 are unable to form interstrand cross-links (data not shown). Regarding the 
tetrahydrobenzopsoralen derivatives 11, 15 and 18, Figure 2a shows the results obtained by 
denaturation-renaturation experiments, in comparison with 8-MOP. 
 
 
Figure 2a. Cross-linking of compounds 11, 15, 18 and 8-MOP to double stranded DNA 
(nucleotide/drug=75) as a function of irradiation time. 
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From the behaviors shown in Figure 2a it can be noted that a noticeable difference appears 
between the ability to induce cross-links exerted by 15 and 18 with respect to that of 11. In 
particular, the two tetrahydrobenzopsoralens characterized by the condensation of the fourth ring 
to the pyrone side of the psoralen chromophore (compounds 15 and 18) show a negligible 
capacity to induce cross-links. Also, the derivative carrying the fourth condensed ring at the 4’,5’ 
furan side double bond (compound 11) is able to exert a much higher capacity, even considerably 
higher in comparison with that induced by the reference drug 8-MOP. These overall results 
appear to be in agreement with previous studies where the ability to induce cross-links of furan 
side14 and pyrone side15 tetrahydrobenzopsoralens was evaluated. 
Denaturation-renaturation experiments was performed also for cyclopentenepsoralen 
derivatives 4, 7 and 9. The results shown in Figure 2b indicate for these compounds a remarkable 
ability to give rise to cross-links with double stranded DNA. Indeed, in the presence of both 4, 7 
and 9, the double helix shows a renaturation capacity higher with respect to that induced by 8-
MOP. 
 
Figure 2b. Cross-linking of compounds 4, 7, 9 and 8-MOP to double stranded DNA 
(nucleotide/drug=75) as a function of irradiation time. 
 
Furthermore, similarly to tetrahydrobenzopsoralens 11, 15 and 18, also for the cyclopentene 
derivatives this capacity appears dependent from the position of the fourth ring. In detail, 
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compound 4, characterized by the condensation of the cyclopentane at the level of furan side, is 
able to induce cross-links more efficiently with respect to the congeners carrying the 
cyclopentane ring condensed at the 4’,5’ double bond (7 and 9). 
Taken together, this results seem to indicate that the steric hyndrance, due to the presence of 
a saturated ring at the level of 3,4 photoreactive double bond of the furan side monoadduct, 
hindered the subsequent monoaddition. On the contrary, once the furan side monoadduct takes 
place, the presence of a fourth ring at the 4’,5’ level probably does not affect significantly the 
subsequent photoaddition involving the 3,4 pyrone side. 
Comparing the above data with those reported in Table 1, it is possible to conclude that, 
notwithstanding the fact that cross-links undoubtedly constitute lethal damage for the cell, there 
is not a linear relationship between the capacity to give rise to this molecular event and the 
ability to induce cell death. Consequently, it is reasonable to assume that they are not the leading 
molecular consequence accountable for the cellular cytotoxicity derived from UVA treatment in 
the presence of these derivatives. 
Similarly, despite a previous hypothesis of a correlation between furocoumarin capacity for 
crosslinking DNA and skin phototoxicity,25 the obtained results (see Fig. 2a and 2b and Table 1) 
appear in conflict with this assumption and indicate, rather, the existence of complex 





The photobiological behaviour of cyclopentene- (4, 7 and 9), tetrahydrobenzo- (11, 15 and 18) 
and benzo-psoralens (12, 16 and 20), carrying two methyl groups in different positions of the 
psoralen cromophore, was investigated. In particular, for all the tested compounds a noticeable 
and comparable photoantiproliferative activity was scored. Interestingly, in HeLa cells they 
appears to exert an antiproliferative activity from 8 to 22 times greater with respect to that of 8-
MOP. On the other hand, evaluation of skin phototoxicity brought out significant differences 
depending on the type of the fourth ring condensed to the psoralen moiety. In particular, the 
following order in inducing skin photosensitisation is detected: 8-MOP>cyclopentene-
psoralens>tetrahydrobenzo-psoralens>benzo-psoralens. In this connection, it is noteworthy that 
in our experimental conditions the derivatives 12, 16 and 20 appear unable to induce the 
appearance of any erythema, even when tested at a concentration higher than that of 8-MOP. 
As regards the ability to interact with DNA, the tetracyclic derivatives seem to act like the 
parent compound. The capacity to photoreact with the macromolecule was demonstrated, and in 
particular, a preference toward the pyrimidine base thymine was highlighted. As regards the 
capacity to behave as bifunctional molecules, both tetrahydrobenzopsoralens and 
cyclopentenepsoralens are able to induce interstrand cross-links. Nevertheless, the capacity to 
photoreact with the opposite DNA strands appears strongly dependent on the photoreactive side 
at which the condensation of the fourth ring occurs. In detail, condensation at the level of the 
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pyrone double bond strongly prevents the formation of cross-links as compared with 
condensation on the furan side. Furthermore, it can be underlined that this inhibitory effect is 
more pronounced for tetrahydrobenzopsoralens than for cyclopentenepsoralens and it could be 
attributable to the wider steric hindrance of the cyclohexane, so that it could influence more 
strongly the correct superimposition of the photoreactive double bonds during the bifunctional 
photoaddition. 
In conclusion, the study of the photobiological behavior of structurally correlated 
tetracyclic psoralen derivatives allowed us to highlight some relationships between molecular 
events and structural properties and this knowledge could constitute a preliminary goal in the 





General Procedures. Melting points are uncorrected and were determined in a Reichert Kofler 
thermopan or in capillary tubes in a Büchi 510 apparatus. IR spectra were recorded in a Perkin-
Elmer 1640FT spectrometer (KBr disks, υ in cm-1). 1H-NMR (300 MHz) and 13C-NMR (75.4 
MHz) spectra were recorded in a Bruker AMX spectrometer, using TMS as internal standard 
(chemical shifts in δ values, J in Hz). Mass spectrometry was carried out on a Kratos MS-50 or 
on a Varian AT-711 spectrometer. Elemental analyses were performed by a Perkin-Elmer 240B 
microanalyser and were within ±0.4% of calculated values in all cases. Flash chromatography 
(FC) was performed on silica gel (Merck 60, 230-400 mesh); analytical TLC was performed on 
precoated silica gel plates (Merck 60 F254, 0.25 mm). 
 
4,8-Dimethyl-7-(2′-oxocyclopentyloxy)coumarin (3). To a solution of 2 (500 mg, 2.62 mmol)26 
in dry acetone (30 mL) were added 2-chlorocyclopentanone (525 µL, 623 mg, 5.25 mmol) and 
K2CO3 (726 mg, 5.25 mmol), and the reaction mixture was refluxed for 24 h. The precipitate was 
filtered out and the solvent concentrated under reduced pressure. The crude product was purified 
by FC using  hexane/ethyl acetate (3:1) as eluent, yielding pure 3 (644 mg, 90.1%). Mp 187oC. 
IR: 2922, 1722, 1605, 1288, 1119. 1H NMR (CDCl3): 2.09 (m, 2H + 2H, H-4′ + H-5′), 2.31 (s, 
3H, Me-C8), 2.39 (d, J = 1.1 Hz, 3H, Me-C4), 2.47 (m, 2H, H-3′), 4.70 (t, J = 7.8 Hz, 1H, H-1′), 
6.14 (d, J = 1.1 Hz, 1H, H-3), 6.94 (d, J = 8.8 Hz, 1H, H-6), 7.39 (d, J = 8.8 Hz, 1H, H-5). 13C 
NMR (CDCl3): 8.40 (Me-C8), 17.26 (Me-C4), 18.70 (C4′), 29.67 (C5′), 35.24 (C3′), 79.97 (C1′), 
109.52 (C3), 112.12 (C6), 114.35 (C8), 115.15, 122.28 (C5), 152.64, 152.74, 158.69, 161.52 
(C2), 213.41 (C2′). MS m/z (%): 273([M+1]+, 16), 272(M+, 92), 201(32), 190(90), 162(100), 
115(26). Anal. C16H16O4: C, H. 
4′,5′-Cyclopentene-4,8-dimethylfuro[3,2-g]coumarin (4). A mixture of 3 (510 mg, 1.87 mmol) 
and 1M NaOH (30 mL) was refluxed for 24 h, cooled, and acidified with 3M HCl. The 
precipitate was recovered by filtration and washed with water. The crude product was purified by 
FC using hexane/ethyl acetate (19:1) as eluent, yielding pure 4 (143 mg, 30%). Mp 153oC. IR: 
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2922, 2850, 1706, 1558, 1480, 1396, 1125, 1092. 1H NMR (CDCl3): 2.48 (s, 3H, Me-C8), 2.57 
(s, 3H, Me-C4), 2.59 (m, 2H, CH2CH2CH2), 2.78 (m, 2H, CH2-C5′), 2.90 (m, 2H, CH2-C4′), 6.24 
(s, 1H, H-3), 7.41 (s, 1H, H-5). 13C NMR (CDCl3): 8.9 (Me-C8), 19.7 (Me-C4), 23.1 
(CH2CH2CH2), 25.6 (CH2-C4′), 27.6 (CH2-C5′), 110.6 (C8), 111.3 (C3), 113.2 (C5), 116.2, 
121.7, 123.3, 148.9, 153.8, 161.4, 162.1, 164.9 (C2). MS m/z (%): 254(M+, 80), 226(M+-CO, 
100), 225(98), 199(18), 183(15), 149(56). Anal. C16H14O3: C, H. 
7-(β-Bromoallyloxy)-3,4-cyclopentene-8-methylcoumarin (8). This compound was prepared 
from 5 (1.0 g, 4.62 mmol)2, K2CO3 (958 mg, 6.93 mmol) and 2,3-dibromopropene (716 µL, 1.38 
g, 6.93 mmol) in the same way as 3. The crude product was purified by FC using hexane/ethyl 
acetate (6:1) as eluent, yielding pure 8 (1.2 g, 77.7%). Mp 140oC. IR: 2919, 1716, 1611, 1373, 
1282, 1109, 803. 1H NMR (CDCl3): 2.19 (m, 2H, CH2CH2CH2), 2.38 (s, 3H, Me-C8), 2.90 (t, J 
= 7.5 Hz, 2H, CH2-C4), 3.03 (t, J = 7.6 Hz, 2H, CH2-C3), 4.72 (s, 2H, CH2O), 5.71 (d, J = 
2.1 Hz, 1H, C=CH), 6.01 (d, J = 2.1 Hz, 1H, C=CH), 6.77 (d, J = 8.6 Hz, 1H, H-6), 7.23 (d, J = 
8.6 Hz, 1H, H-5). 13C NMR (CDCl3): 8.61 (Me-C8), 22.56 (CH2CH2CH2), 30.40 (CH2-C4), 
32.07 (CH2-C3), 72.02 (CH2O), 108.09 (C6), 113.26 (C8), 114.81, 118.00 (CH2=C), 122.47 
(C5), 124.94, 126.52, 153.40, 156.40, 157.63, 160.58 (C2). MS m/z (%): 336([M+2]+, 12), 
335(M+, 12), 255(76), 215(29), 187(100), 128(15). Anal. C16H15BrO3: C, H. 
3,4-Cyclopentene-5′,8-dimethylfuro[3,2-g]coumarin (9). A solution of 8 (218 mg, 0.65 mmol) 
in N,N-diethylaniline (5 mL) was refluxed for 40 h. The solution was cooled, and ethyl ether was 
added (35 mL). The precipitate was filtered, washed with 1N NaOH (3 x 25 mL) and 6N HCl (2 
x 25 mL), the extract was dried (Na2SO4), and the solvent was evaporated under reduced 
pressure. The crude product was purified by FC using hexane/ethyl acetate (6:1) as eluent, 
yielding pure 9 (85 mg, 52.0%). Mp 213oC. IR: 3068, 2923, 1716, 1593, 1173, 1101, 807. 1H 
NMR (CDCl3): 2.20 (m, 2H, CH2CH2CH2), 2.48 (d, J = 1.0 Hz, 3H, Me-C5′), 2.56 (s, 3H, Me-
C8), 2.91 (t, J = 7.5 Hz, 2H, CH2-C4), 3.08(t, J = 7.6 Hz, 2H, CH2-C3), 6.37 (d, J = 1.0Hz, 1H, 
H-4′), 7.28 (s, 1H, H-5). 13C NMR (CDCl3): 8.69 (Me-C8), 14.20 (Me-C5′), 22.44 
(CH2CH2CH2), 30.54 (CH2-C4), 32.40 (CH2-C3), 102.50 (C4′), 108.92 (C8), 112.09 (C5), 
114.77, 124.96, 125.25, 149.41, 154.93, 156.98, 157.12, 160.79 (C2). MS m/z (%): 255([M+1]+, 
17), 254(M+, 97), 226(100), 199(48), 183(26), 153(12). Anal. C16H14O3: C, H. 
7-(β-Bromoallyloxy)-3,4-cyclohexene-8-methylcoumarin (17). This compound was prepared 
from 13 (1.1 g, 4.8 mmol)3, K2CO3 (1.0 g, 7.2 mmol) and 2,3-dibromopropene (747 µL, 1.4 g, 
7.2 mmol) in the same way as 3. The crude product was purified by FC using hexane/ethyl 
acetate (6:1) as eluent, yielding pure 17 (1.27 g, 75.9%). Mp: 135-136oC. IR: 3071, 2935, 1708, 
1605, 1114, 755. 1H NMR (CDCl3): 1.82 (m, 4H, CH2(CH2)2CH2), 2.35 (s, 3H, Me-C8), 2.56 (m, 
2H, CH2-C4), 2.72 (m, 2H, CH2-C3), 4.71 (s, 2H, CH2O), 5.76 (d, J = 1.6 Hz, 1H, C=CH), 6.01 
(d, J = 1.6 Hz, 1H, C=CH), 6.75 (d, J = 8.8 Hz, 1H, H-6), 7.35 (d, J = 8.8 Hz, 1H, H-5). 13C 
NMR (CDCl3): 8.78 (Me-C8), 21.86 (CH2-CH2C3), 22.11 (CH2-CH2C4), 24.31 (CH2-C3), 25.65 
(CH2-C4), 72.36 (CH2O), 108.32 (C6), 114.80 (C8), 115.04, 118.36 (CH2=C), 121.26, 121.35 
(C5), 127.03, 147.64, 151.57, 157.47, 162.60 (C2). MS m/z (%): 350 ([M+2]+, 4), 349 (M+, 22), 
269 (89), 229 (100), 201 (58), 187 (40). Anal. C17H17BrO3: C, 58.44; H, 4.87. 
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3,4-Cyclohexene-5′,8-dimethylfuro[3,2-g]coumarin (18). This compound was prepared from 
17 (2.5 g, 7.1 mmol) and N,N-diethylaniline (55 mL), in the same way as 9 from 8. The residue 
was purified by FC using hexane/ethyl acetate (6:1) as eluent, yielding 18 (1.1 g, 57.1%). 
3,4-Benzo-7-(β-bromoallyloxy)-8-methylcoumarin (19). A solution of 17 (106 mg, 0.30 mmol) 
and DDQ (137 mg, 0.60 mmol) in toluene (15 mL) was refluxed for 5 h. The mixture was 
cooled, the precipitate collected, the solvent evaporated under reduced pressure, and the resulting 
residue purified by FC using CHCl3 as eluent, giving pure 19 (85 mg, 81.7%). Mp: 128oC. IR: 
2921, 1726, 1608, 1470, 1283, 1115, 891, 766. 1H NMR (CDCl3): 2.38 (s, 3H, Me-C8), 4.72 (s, 
2H, CH2O), 5.72 (d, J = 1.9 Hz, 1H, C=CH), 6.03 (d, J = 1.9 Hz, 1H, C=CH), 6.80 (d, J = 
8.8 Hz, 1H, H-6), 7.49 (m, 1H, CH-CHC4), 7.78 (m, 1H + 1H, CH-CHC3 + H-5), 7.98 (d, J = 
8.0 Hz, 1H, CH-C3), 8.34 (d, J = 8.0 Hz, 1H, CH-C4). 13C NMR (CDCl3): 8.95 (Me-C8), 72.33 
(CH2O), 108.68 (C6), 112.36, 115.67, 118.39 (C=CH2), 120.25, 120.84 (CH-C4), 121.63 (CH-
CHC3), 127.01, 128.18 (C5), 130.75 (CH-CHC4), 135.12 (CH-C3), 135.57, 150.66, 157.49, 
161.78 (C2). MS m/z (%): 347 ([M+2]+, 2), 345 (M+, 12), 344 (13), 265 (60), 225 (100), 171 
(17). Anal. C17H13BrO3: C, H. 
3,4-Benzo-5′,8-dimethylfuro[3,2-g]coumarin (20). This compound was prepared from 19 
(1.0 g, 2.9 mmol) and N,N-diethylaniline, in the same way as 9 from 8. The crude product was 
purified by FC using hexane/ethyl acetate (6:1) as eluent, yielding pure 20 (397 mg, 52.0%). Mp: 
230-231oC. IR: 2925, 1722, 1610, 1440, 1115, 850. 1H NMR (CDCl3): 2.45 (d, J = 1.2 Hz, 3H, 
Me-C5′), 2.55 (s, 3H, Me-C8), 6.60 (d, J = 1.2 Hz, 1H, H-4′), 7.47 (m, 1H, CH-CHC3), 7.74 (m, 
2H, CH-CHC4), 7.94 (s, 1H, H-5), 8.11 (d, J = 8.0 Hz, 1H, CH-C4), 8.32 (d, J = 8.0 Hz, 1H, 
CH-C3). 13C NMR (CDCl3): 8.56 (Me-C8), 14.01 (Me-C5′), 101.80 (C4′), 110.00 (C5), 110.10 
(C8), 113.65 (C4a), 120.87 (C6), 121.40 (CH-C4), 124.62 (C3), 127.88 (CH-CHC3), 130.35 
(CH-C3), 134.50 (CH-CHC4), 135.00 (C4), 147.10 (C8a), 154.98 (C7), 156.80 (C5′), 161.47 
(C2). MS m/z (%): 265 ([M+1]+, 15), 264 (M+, 100), 235 (19), 207 (10), 178 (17), 152 (10). 
Anal. C17H12O3: C, H. 
Photobiological methods. Cell cultures. HL-60 and HeLa cells were grown in RPMI 1640 
(Sigma Chemical Co.) supplemented with 15% heat-inactivated fetal calf serum (Biological 
Industries) and Nutrient Mixture F-12 [HAM] (Sigma Chemical Co.) supplemented with 10% 
heat-inactivated fetal calf serum (Biological Industries), respectively. 100 U/mL penicillin, 
100 µg/mL streptomycin and 0.25 µg/mL amphotericin B (Sigma Chemical Co.) were added to 
both media. The cells were cultured at 37°C in a moist atmosphere of 5% carbon dioxide in air. 
Irradiation procedure. Irradiations were performed by means of Philips HPW 125 lamps 
equipped with a Philips filter emitting over 90% at 365 nm. Irradiation intensity was checked on 
a UV-X radiometer (Ultraviolet Products Inc., Cambridge, UK) for each experimental procedure. 
Inhibition growth assays. HeLa cells (105) were seeded into each well of a 24-well cell culture 
plate. After incubation for 24 h, the medium was replaced with an equal volume of Dulbecco′s 
modified Eagle medium (DMEM, Sigma Chemical Co.) without phenol red, and various 
concentrations of the test agent were added. One hour later the cells were irradiated with a UVA 
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dose of 0.793 J cm-2. After irradiation, the medium containing the compounds was removed, and 
the cells were incubated in complete F-12 medium for 24 hours. 
HL-60 cells (105) were seeded into each well of a 24-well cell culture plate. After incubation for 
24 hours, various concentrations of the test agents were added in complete medium. The cells 
were kept in the dark for 1 hour, irradiated with a UVA dose of 0.793 J cm-1 and then incubated 
for a further 24 hours. 
In the case of the experiments carried out in the dark, the cells, both HeLa and HL-60 were 
seeded (105) and incubated for 24 hours. Then the test agents were added and the cells were 
incubated for a further 24 hours. 
A trypan blue assay was performed to determine cell viability. Cytotoxicity data were expressed 
as IC50 values, i.e., the concentrations of the test agent inducing 50% reduction in cell numbers 
compared with control cultures. 
Skin phototoxicity. Skin phototoxicity was tested on depilated albino guinea pigs (outbred 
Dunkin-Hartley strain), as previously reported.27 An ethanol solution of each new compound was 
applied topically to the skin up to 50 µg/cm2. For 8-MOP the concentration used was 10 µg/cm2. 
The animals were then kept in the dark for 45 min and the treated skin was irradiated with 20 kJ m-2 
of UVA; erythema was scored after 48 h. 
Nucleic acid. Salmon testes DNA was purchased from Sigma Chemical Company (Cat. D-
1626). Its hypochromicity, determined according to Marmur and Doty,28 was over 35%. The 
DNA concentration was determined using extinction coefficient 6600 M-1cm-1 at 260 nm. 
 
Preparation of adducts. Volumes of concentrated solutions of the examined compound were 
added to salmon testes DNA in ETN solution (1.5x10-3M) to achieve a DNA/compound ratio of 
about 80. The mixture was irradiated in a glass dish with four Philips HPW 125 lamps, arranged 
two above and two below the dish, at a distance of 7 cm, for 120 min at room temperature. After 
irradiation the DNA was precipitated with NaCl (up to 1 M concentration) and cool ethanol (2 
volumes), the precipitated DNA was collected, washed with 80% ethanol, dried and then 
dissolved in a measured volume of buffer. The final solution was made 0.5 N with HCl, heated at 
100 °C for 2 h, neutralised and extracted exhaustively with CHCl3. After this procedure the 
organic layers were collected, dried under high vacuum and dissolved in ethanol and the adduct 
was separated on TLC plates and eluted with 100% ethanol. UV spectra were recorded on a 
Perkin Elmer model Lambda 5 spectrophotometer. The 1H and 13C assignment was obtained by 
utilising HMQC and HMBC spectra on a Bruker Avance DMX600 instrument. Mass 
spectrometry measurements were performed on a ElectroSpray Ionization (ESI) Time of Flight 
(ToF) instrument (mod. Mariner, Perseptive-Biosystem) by dissolving the samples in 
water/acetonitrile/formic acid (50:49:1) solution. 
 
Photoreversal of adducts. Ethanol solution of the adduct (ca. 20 µg/mL) was irradiated in 
quartz cuvettes with a mineral lamp (254 nm). The photosplitting reaction was followed 
spectrophotometrically. 
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Evaluation of interstrand cross-links in vitro. Evaluation of cross-links was carried out by 
measuring the renaturation capacity of cross-linked double helix after thermal denaturation. 
Aliquots of aqueous solutions of salmon testes DNA (Sigma Co.), alone and at [nucleic 
acid]/[drug]=75, were introduced into calibrated glass tubes, immersed in a thermostatically 
controlled bath, and then irradiated for various periods of time. After irradiation the samples 
were thermally denatured (95°C for 15 min) and quickly cooled in ice. The renaturation capacity 
of DNA, due to cross-link formation, was investigated by recording absorbance at 260 nm. Data 
were expressed in terms of non-renaturated fraction of irradiated compound-DNA complex 
relative to irradiated DNA, as suggested by Blais et al.29 In detail: 
 
( )
( ) DNA nativeR










where AN and AR are, respectively, the optical densities measured at 260 nm of DNA before heat 
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